← Research library

[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors].

Observational study · 2019

What was studied
31 adults with generalized anxiety disorder
Main finding
A 31-person, 21-day uncontrolled GB-115 pilot reported improvements in anxiety, attention and sleep; it does not quantify an advantage over placebo or standard drugs.

Reported findings and study design

A 31-person, 21-day uncontrolled GB-115 pilot reported improvements in anxiety, attention and sleep; it does not quantify an advantage over placebo or standard drugs.

31 adults with generalized anxiety disorder, aged 22–53: 22 women, 9 men.

Dose, route and schedule

GB-115 was studied as 1 mg tablets during 21 days of treatment. The authors identified 6 mg/day as the effective dose in this report; the abstract does not give a divided-dose schedule.

Protocol source ↗ · Indexed publication abstract

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Anxiety and cognitive measuresReported favorable changes; no numerical scale deltas in indexed abstract
Participants31 (22 women; 9 men)
Studied dose and durationEffective dose described as 6 mg/day; 21 days

This pilot is distinct from the larger phase II/III reports, and possible overlap with later 25-person conference analyses remains flagged.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Uncontrolled pilot evidence; expectancy and repeated-testing effects remain possible.
  • Later 25-patient conference analyses may overlap and are not counted as independent replication.

Source details

Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.

Abstract reviewed

Sources checked

Citation

Uncontrolled human reportEnglish abstract

Neznamov GG, Dorofeeva OA, Metlina MV, Syunyakov TS, Minaev SV, Ivashkina NY, Martyanov VA, Seredenin SB. [Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Study source ↗ · DOI 10.17116/jnevro201911908153 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards